Study Enrollment


Your details will not be published or shared.

Clinical Trial

Ponatinib-3001: A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib versus Imatinib, Administered in Combination with Reduced-intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

This study compares two medications, ponatinib and imatinib, to see which works better in people who have been newly diagnosed with the disease called Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).


Eligibility Criteria

  • Must be 18 years of age or older Newly diagnosed Ph+ or BCR-ABL1-positive ALL

Contact Information

    Kelly Jenkins, RN

    (706) 721-1206

   kejenkins@augusta.edu

RESEARCH. INNOVATION. DISCOVERY.